Actovegin solution

General characteristics. Structure:

1 ml contains:
active agent: blood components – deproteined hemoderivative of blood of calfs, соотв. 40 mg of dry weight, the chloride of 26,8 mg containing sodium.
Excipient: water for injections.

Description: transparent, yellowish solution, almost free from particles.

Pharmacological properties:

Pharmacodynamics. Antigipoksant. АКТОВЕГИН© is hemoderivative which is received by means of dialysis and ultrafiltration (there take place connections with molecular weight less than 5000 дальтон). Positively influences transport and utilization of glucose, stimulates oxygen consumption (that leads to stabilization of plasma membranes of cells at ischemia and to decrease in formation of lactates) possessing, thus, anti-hypoxemic action which begins to be shown the latest in 30 min. after parenteral administration and reaches a maximum on average in 3 h (2-6 h). АКТОВЕГИН© increases concentration of adenosinetriphosphate, adenosinediphosphate, phosphocreatinine, and also amino acids – a glutamate, aspartate and piperidic acid.

Pharmacokinetics. By means of pharmacokinetic methods it is impossible to study pharmacokinetic indicators of the drug AKTOVEGIN® as it consists only of physiological components which usually is present at an organism.
So far decrease in pharmacological effect of hemoderivatives at patients with the changed pharmacokinetics is not revealed (for example, a liver or renal failure, the metabolism changes connected with old age and also features of metabolism at newborns).

Indications to use:

• Metabolic and vascular disorders of a brain (including ischemic stroke, craniocereberal injury).
• Peripheral (arterial and venous) vascular disorders and their effects (arterial angiopatiya, trophic ulcers).
• Healing of wounds (ulcers of various etiology, burns, trophic disturbances (decubituses), disturbance of processes of healing of wounds).
• Prevention and treatment of radiation injuries of skin and mucous membranes at radiation therapy.

Route of administration and doses:

Vnutriarterialno, intravenously (including in the form of infusion) and intramusculary. Due to potentiality of development of anaphylactic reactions, it is recommended to carry out the test prior to infusion. The instruction for use of ampoules with a break point:

To arrange an ampoule tip a point up! To break off a tip as it is represented in the drawing. 
To arrange an ampoule tip a point up! Carefully tapping with a finger and stirring up an ampoule to allow solution to flow down from a tip of an ampoule down.

Depending on weight of a clinical picture, the initial dose makes 10-20 ml/days intravenously or vnutriarterialno; further 5 ml intravenously or 5 ml intramusculary.
At introduction in the form of infusion 10-20 ml АКТОВЕГИНа© add to 200-300 ml of the main solution (0,9% solution of sodium chloride or 5% dextrose solution). Rate of administering: about 2 ml/min.
Metabolic and vascular disorders of a brain: in an initiation of treatment of 10 ml intravenously daily within two weeks, further 5-10 ml intravenously 3-4 times a week within not less than 2 weeks.
Ischemic stroke: 20-50 ml in 200-300 ml of the main solution intravenously kapelno daily within 1 week, further on 10-20 ml intravenously kapelno – 2 weeks.
Peripheral (arterial and venous) vascular disorders and their effects: 20-30 ml of drug in 200 ml of the main solution vnutriarterialno or intravenously daily; duration of treatment is about 4 weeks.
Healing of wounds: 10 ml intravenously or 5 ml intramusculary daily or 3-4 times a week depending on healing process (in addition to topical treatment by the drug AKTOVEGIN© in dosage forms for topical administration).
Prevention and treatment of radiation injuries of skin and mucous membranes at radiation therapy: the average dose makes 5 ml intravenously daily in breaks of radiative effects.
Radiation cystitis: daily 10 ml transuretralno in combination with therapy by antibiotics.

Features of use:

In case of an intramuscular route of administration enter slowly no more than 5 ml. Because of possibility of anaphylactic reaction it is recommended to carry out a trial injection (2 ml intramusculary).
Solution for injections has slightly yellowish shade. Intensity of coloring can vary from one party to another depending on features of the used starting materials, however it has not an adverse effect on activity of drug or its portability.
Do not use the opaque solution or solution containing particles.
After opening of an ampoule, solution cannot be stored.

Side effects:

Allergic reactions (skin rash, dermahemia, hyperthermia) up to an acute anaphylaxis.

Interaction with other medicines:

Now it is unknown.

Contraindications:

Гиперчувствителыюсть to the drug AKTOVEGIN® or similar drugs, dekompensirovanny heart failure, a fluid lungs, an oliguria, an anury, a liquid delay in an organism. With care: hyperchloremia, hypernatremia.

Use at pregnancy and a lactation: use of drug did not cause negative impact on mother or a fruit in pregnant women. However at use for pregnant women it is necessary to consider potential risk for a fruit.

Storage conditions:

Period of validity of 5 years. Not to use after a period of validity. At a temperature not above 25 °C in the place protected from light. To store in the place unavailable to children!

Issue conditions:

According to the recipe

Packaging:

Solution for injections of 40 mg/ml.
On 2, 5, 10 ml of drug in colourless glass ampoules (type I, Evr. фарм.) with a break point. On 5 ampoules in a plastic blister strip packaging. On 1 or 5 blister strip packagings with the application instruction place in a cardboard pack. On a pack paste transparent protective stickers of a round form with holographic texts and control of the first opening.